Welcome to the full-year 2024 Novo Nordisk earnings conference call. [Operator instructions] Please be advised that today's ...

LOS ANGELES, CA / ACCESS Newswire / February 5, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a ...

The Danish maker of Ozempic and Wegovy reported a 25 percent increase in sales to $40.6 billion, but said it expected slower ...

On the charts, today's pop has NVO on track to snap a three-day losing streak. The stock still hasn't recovered from its mid-December bear gap, after which it hit a Jan. 17, 52-week low of $78.17 amid ...

The Danish pharmaceutical company expects demand for obesity and diabetes drugs to rise, but forecasts sales growth to slow down this year. Read more.

Novo Nordisk has a dominant position in diabetes and weight-loss drugs, strong financial growth outlook, and great potential.

Obesity drug maker Novo Nordisk forecast slower growth this year after Wegovy sales more than doubled in the final quarter of ...

The suggestion came out of the blue and underlined the risk of more policy uncertainty and market volatility ahead. Gold hit ...

Container shipping liner Hapag-Lloyd will be able to cope with the advent of U.S. tariffs on Chinese products, its chief executive told reporters on Tuesday. Ciara Lee reports.

Yields on two-year Treasuries eased 2 basis points on the day to below 4.2%, which in turn took some sheen off the dollar.

Global stocks fell on Wednesday, after disappointing earnings from Alphabet knocked Wall Street futures, while the dollar ...

US equity futures dropped as investors navigate the trade war and a busy slate of earnings from some of the world’s biggest ...